Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants

被引:144
作者
Rauser, G
Einsele, H
Sinzger, C
Wernet, D
Kuntz, G
Assenmacher, M
Campbell, JDM
Topp, MS
机构
[1] Univ Tubingen, Med Klin 2, D-72076 Tubingen, Germany
[2] Miltenyi Biotec, Bergisch Gladbach, Germany
关键词
D O I
10.1182/blood-2003-09-3056
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adoptive transfer of cytomegalovirus (CMV)-specific T cells can restore long-lasting, virus-specific immunity and clear CMV viremia in recipients of allogeneic stem cell transplants if CD4+ and CD8+ CMV-specific T cells are detected in the recipient after transfer. Current protocols for generating virus-specific T cells use live virus, require leukapheresis of the donor, and are time consuming. To circumvent these limitations, a clinical-scale protocol was developed to generate CMV-specific T cells by using autologous cellular and serum components derived from a single 500-mL blood draw. CMV-specific T cells were stimulated simultaneously with CMV-specific major histocompatibility complex class 1 (MHC 1)-restricted peptides and CMV antigen. Activated T cells were isolated with the interferon-gamma (IFN-gamma) secretion assay and expanded for 10 days. In 8 randomly selected, CMV-seropositive donors, 1.34 x 10(8) combined CD4(+) and CD8(+) CMV-specific T cells, on average, were generated, as determined by antigen-triggered IFN-gamma production. CMV-infected fibroblasts were efficiently lysed by the generated T cells, and CMV-specific CD4(+) and CD8(+) T cells expanded if they were stimulated with natural processed antigen. On the other hand, CD4(+) and CD8(+) T cell-mediated alloreactivity of generated CMV-specific T-cell lines was reduced compared with that of the starting population. In conclusion, the culture system developed allowed the rapid generation of allodepleted, highly enriched, combined CD4(+) and CD8(+) CMV-specific T cells under conditions mimicking good manufacturing practice. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:3565 / 3572
页数:8
相关论文
共 37 条
[1]   Haploidentical stem cell transplantation in leukemia [J].
Aversa, F ;
Velardi, A ;
Tabilio, A ;
Reisner, Y ;
Martelli, MF .
BLOOD REVIEWS, 2001, 15 (03) :111-119
[2]   Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay [J].
Becker, C ;
Pohla, H ;
Frankenberger, B ;
Schüler, T ;
Assenmacher, M ;
Schendel, DJ ;
Blankenstein, T .
NATURE MEDICINE, 2001, 7 (10) :1159-1162
[3]   Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-γ secretion assay [J].
Bissinger, AL ;
Rauser, G ;
Hebart, H ;
Frank, F ;
Jahn, G ;
Einsele, H .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (10) :1178-1184
[4]   Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [J].
Boeckh, M ;
Bowden, RA ;
Gooley, T ;
Myerson, D ;
Corey, L .
BLOOD, 1999, 93 (05) :1781-1782
[5]  
Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO
[6]  
2-3
[7]   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution [J].
Chakrabarti, S ;
Mackinnon, S ;
Chopra, R ;
Kottaridis, PD ;
Peggs, K ;
O'Gorman, P ;
Chakraverty, R ;
Marshall, T ;
Osman, H ;
Mahendra, P ;
Craddock, C ;
Waldmann, H ;
Hale, G ;
Fegan, CD ;
Yong, K ;
Goldstone, AH ;
Linch, DC ;
Milligan, DW .
BLOOD, 2002, 99 (12) :4357-4363
[8]   CYTOMEGALOVIRUS REACTIVATION AND TUMOR-NECROSIS-FACTOR [J].
DOCKE, WD ;
PROSCH, S ;
FIETZE, E ;
KIMEL, V ;
ZUCKERMANN, H ;
KLUG, C ;
SYRBE, U ;
KRUGER, DH ;
VONBAEHR, R ;
VOLK, HD .
LANCET, 1994, 343 (8892) :268-269
[9]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
[10]  
Eckle T, 2000, BLOOD, V96, P3286